INSM1 is a useful neuroendocrine marker to differentiate pancreatic serous cystadenoma from pancreatic well-differentiated neuroendocrine tumors in cytology and surgical specimens

Zhikai Chi; Jing Xu; Dipti M Karamchandani; Lan Peng

doi:10.1016/j.anndiagpath.2024.152304

INSM1 is a useful neuroendocrine marker to differentiate pancreatic serous cystadenoma from pancreatic well-differentiated neuroendocrine tumors in cytology and surgical specimens

Ann Diagn Pathol. 2024 Apr 9:71:152304. doi: 10.1016/j.anndiagpath.2024.152304. Online ahead of print.

Authors

Zhikai Chi¹, Jing Xu², Dipti M Karamchandani², Lan Peng²

Affiliations

¹ Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Electronic address: zhikai.chi@utsouthwestern.edu.
² Department of Pathology, The University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

PMID: 38614035
DOI: 10.1016/j.anndiagpath.2024.152304

Abstract

Introduction: Differentiating pancreatic serous cystadenoma (SCA) from well-differentiated neuroendocrine tumors (WDNETs) based on histomorphology is critical yet challenging, particularly in small biopsy samples. Our study aimed to examine the expression profile of INSM1 in cytologic and surgical resection specimens from pancreatic SCA to evaluate its potential as a discriminative marker against pancreatic WDNET.

Methods: We characterized INSM1 immunohistochemistry in 34 patients with pancreatic SCA, comprising 23 surgical resections and 11 cytology specimens. As a control, we used 28 cytology specimens from pancreatic WDNET. Clinical information was retrieved through a review of electronic medical records.

Results: All 11 pancreatic SCA cytology specimens and 15 of 23 pancreatic SCA surgical resections exhibited absent INSM1 immunostaining. Each of the remaining eight surgical resection specimens demonstrated 1 % immunoreactivity. In contrast, 27 out of 28 (96 %) pancreatic WDNET cytology specimens were positive for INSM1 immunostaining, with a median immunoreactivity of 90 % and a range of 30-90 %. Overall, INSM1 immunostains perform similarly to chromogranin and synaptophysin in pancreatic SCA.

Conclusions: The results indicate that INSM1 immunohistochemistry staining may serve as a useful neuroendocrine marker to differentiate pancreatic SCA from pancreatic WDNET in clinical practice. To our knowledge, this represents the first large-scale study to evaluate INSM1 immunostaining in surgical and cytology specimens from pancreatic SCA.

Keywords: Differential diagnosis; INSM1; Immunohistochemistry; Pancreatic serous cystadenoma; Pancreatic well-differentiated neuroendocrine tumor.